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Update on safety during pregnancy of biological agents and some
immunosuppressive anti-rheumatic drugs
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and A. Tincani8
A consensus paper concerning the interaction of anti-rheumatic drugs and reproduction was published in 2006, representing data collected
during the year 2004 and 2005. Because of an increasing use of biological agents in women of fertile age, the information was updated for the
years 2006 and 2007. Experts disagree whether TNF-inhibitors should be stopped as soon as pregnancy is recognized or may be continued
throughout pregnancy. Pregnancy experience with abatacept and rituximab is still too limited to prove their safety for the developing fetus.
They must be withdrawn before a planned pregnancy. LEF has not been proven to be a human teratogen. Registries of transplant recipients
have shown that cyclosporin (CsA) and tacrolimus do not increase the rate of congenital anomalies, whereas mycophenolate mofetil (MMF)
clearly carries a risk for congenital anomalies. Prophylactic withdrawal of drugs before pregnancy is mandatory for abatacept, rituximab, LEF
and MMF. Data remain insufficient for gonadal toxicity of immunosuppressive drugs in men and for excretion of these drugs in human breast
milk.
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Introduction
During the last 20 yrs, several new immunosuppressive drugs have
been introduced into the therapy of rheumatic diseases. Given that
rheumatic diseases disproportionately affect women of child-
bearing age, the safety of new drugs regarding birth defects,
miscarriages or pre-term delivery is of concern. A consensus paper
concerning the interaction of anti-rheumatic drugs and reproduc-
tion was published in 2006 [1], representing data collected during
the year 2004 and 2005. Because of an increasing use of biological
agents we now update this information for the years 2006 and
2007, using a literature survey performed as reported in 2006.
Biological agents
The manufacturers of the TNF- inhibitors infliximab, etaner-
cept, adalimumab and the B-cell depleting monoclonal antibody
rituximab advise discontinuing these agents prior to a planned
pregnancy. However, numerous new pregnancies inadvertently
occurring during therapy with biological agents in the first
trimester have been reported.
Infliximab
The transplacental passage of infliximab occurs in patients treated
with infliximab in the 2nd and 3rd trimester of pregnancy [2].
Serum levels of infliximab in five infants born of mothers with
IBD treated with infliximab throughout pregnancy were equal to
maternal serum levels and remained detectable up to 6 months of
life [2]. Another child had a serum infliximab level of 39.5 mg/ml
at 6 weeks of age declining during the following 6 months
despite breastfeeding and continued treatment of the mother. No
infliximab was detected in breast milk [3].
A healthy child was born after maternal treatment with 5mg/kg
throughout pregnancy. The child was breastfed without adverse
effects [4]. Another study reported 14 patients with IBD treated
within 3 months of conception. Therapy was continued in 12
women throughout the first and second trimester. The outcome of
pregnancy was reported for 10 pregnancies with delivery of seven
healthy babies, two premature children and one miscarriage [5].
Continuous treatment with infliximab throughout pregnancy of
four women with inflammatory arthritis resulted in the birth of
healthy children [6]. In summary, data for all reported pregnancy
outcomes under treatment with infliximab showed no increase in
miscarriage, prematurity or structural malformations in neonates
compared with non-exposed pregnancies.
Etanercept
Experience from 72 pregnancies of RA patients treated with
etanercept has been published. Most patients were exposed in the
first trimester and three throughout pregnancy [7–9]. The outcome
included seven elective terminations of pregnancy, nine miscar-
riages, 48 live-born children and eight unknown. Two major
malformations occurred, one being trisomy 18 in a miscarried
child, and the other, being born of a mother treated with 100mg
of etanercept weekly throughout pregnancy, showed multiple
anomalies fitting to the so-called VATER (vertebral anomaly,
anal atresia, tracheo-oesophageal fistula, oesophageal atresia,
renal and radial anomalies) association. The child also had
hypospadias and patent foramen ovale [10]. The VATER
association is a rare condition that occurs spontaneously. A
causal relationship between therapy and event cannot be proven.
Adalimumab
Studies in pregnant cynamologous monkeys at doses up to
100mg/kg of adalimumab have not revealed harm to the fetuses.
Twenty-nine first trimester exposures in pregnant RA patients
concluded with 23 live births, one termination, two spontaneous
abortions and three unknown [7, 8, 11]. One premature child was
born with hip dysplasia. Additionally four pregnancies and
treatment throughout pregnancy in patients with Crohn’s disease
have resulted in healthy live-born children [12, 13]. In the cohort
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study of Chambers et al. [11], no increase in the rate of
miscarriage, pre-term birth or structural malformations was
found compared with non-treated and healthy pregnant controls.
The birth weight was within normal range.
Breastfeeding during therapy with TNF- inhibitors
There are no new reports on the passage of etanercept or
adalimumab into human breast milk. Several abstracts and case
reports stated that several children were breastfed during maternal
treatment with TNF- inhibitors and showed normal growth and
development.
Male fertility and therapy with TNF- inhibitors
A study of three men with AS and monotherapy with infliximab
from 8 to 24 months revealed asthenozoospermia and teratozoo-
spermia [14]. The study lacked a control group of male patients
not treated with TNF- inhibitors.
Conclusion
Experience with TNF inhibitors is still too limited to claim safety
during pregnancy. Therefore, experts disagree on their use in
pregnant women. Some advocate to stop them after a positive
pregnancy test, others will continue them throughout pregnancy.
Most reports concern first trimester use of TNF- inhibitors, but
transplacental passage does not occur until week 16 onwards.
Long-term effects of intrauterine exposure to TNF- inhibitors
have not been studied.
At present it is not known whether TNF- inhibitors are
secreted into breast milk and can be ingested by the breastfed
child. Mothers who wish to breastfeed should be informed that
there is insufficient knowledge with which to provide advice.
Similarly there is insufficient data to determine whether or not
TNF- inhibitors have an influence on spermatogenesis.
Abatacept
Abatacept, a CTLA4 and human immunoglobulin fusion protein,
has been introduced as a selective co-stimulation modulator for
the treatment of RA. Abatacept crosses the placenta. Treatment
of pregnant rats and rabbits with up to 29 times the dose given to
humans did not produce malformations in the offspring. At a dose
11 times the dose given to humans, alterations of immune function
was found in the offspring of rats consisting in a 9-fold increase
in the T-cell-dependent antibody response in female pups. The
manufacturer advises against pregnancy during therapy and
recommends contraception until 10 weeks after withdrawal of
the drug. No human pregnancy experience has been published;
therefore, no statement on the safety of abatacept during
pregnancy can be made. Abatacept should not be started or
continued during pregnancy.
Rituximab
Reproductive toxicity studies in non-human primates have not
shown fetotoxicity of rituximab, a monoclonal, B-cell depleting
antibody. Rituximab crosses the placenta from week 16 onwards,
like all IgG immunoglobulins, and achieves fetal serum levels
similar to maternal levels. Published experience includes three
pregnancies in women with lymphomas also treated with
CHOP (a combination of cytotoxic drugs and prednisolone),
and pregnancy in a woman with autoimmune haemolytic anaemia
[15]. Treatment with rituximab was limited to the first trimester in
two, to the second and third in two additional pregnancies. In the
latter, the serum levels of rituximab were similar in the mother and
newborn, and the number of B cells was greatly reduced in these
children. Spontaneous recovery of B-cell numbers occurred in
both infants. After first trimester exposure, lymphopenia but not
B-cell depletion was noted. In all children, IgG levels were normal
and they all showed a normal vaccine response.
In an unpublished safety update report of 2005, 24 pregnancies
exposed to rituximab 1–8 months prior to conception were
registered in patients with malignancies. The 10 pregnancies with
known outcome concluded with the delivery of a live infant
without congenital malformations or serious neonatal or early
childhood infections. Two of the children had low granulocyte
counts after birth, and one also had anaemia and lymphopenia.
Conclusion
Experience with rituximab is too limited to allow any statement
on safety in pregnancy. When administered in the 2nd and 3rd
trimester, B-cell depletion occurs in the fetus. Long-term studies
on B cell and immune function of children exposed in utero are
lacking. Rituximab should be stopped before a planned preg-
nancy, maternal serum levels measured and pregnancy attempted
only after serum levels are negative.
Tacrolimus and mycophenolate mofetil
Recently, tacrolimus and mycophenolate mofetil (MMF) have
been successfully used to treat patients with SLE, particularly
those with a history of lupus nephritis.
Tacrolimus
Experience of pregnancy exposure to tacrolimus stems mainly
from transplant recipients. The studies published in 2006–07
confirm the absence of an increased risk of miscarriage or
congenital anomalies [16].
MMF
The new reports of 2006–07 on use of MMF during 28
pregnancies have confirmed that MMF increases the risk for
congenital malformations including facial dysmorphia and mal-
formation of the ears (microtia and anotia) [17, 18–20]. Recently,
the American Food and Drug Administration (FDA) notified
healthcare providers that use of MMF is associated with increased
risk of first trimester pregnancy loss and increased risk of
congenital malformations, especially external ear and facial
abnormalities including cleft lip and palate, and anomalies of
the distal limbs, heart, oesophagus and kidney.
Conclusion
The available data show that the calcineurin inhibitors do not
increase the risk for congenital abnormalities. Tacrolimus and
cyclosporin (CsA) may therefore be continued during pregnancy
when indicated. The risk for intrauterine growth restriction and
for prematurity is increased both in transplant recipients and
patients with autoimmune diseases regardless of the type of
immunosuppressive therapy. However, at present, it is not known
whether this is related to the underlying maternal condition, or the
frequent use of combinations of immunosuppressive drugs in this
patient population. Human experience confirms the increased risk
of birth defects during therapy with MMF. Based on data from
the United States National Transplantation Pregnancy Registry
and additional post-marketing data, the pregnancy category for
MMF has been changed from Category C (risk of fetal harm
cannot be ruled out) to Category D (positive evidence of fetal
risk). Experts disagree as to the time point of withdrawal of MMF
before a planned pregnancy, but because of its long half-life it
should be discontinued at least 6 weeks before a planned
pregnancy.
LEF
A case report described a child exposed to LEF during the first
16 weeks of pregnancy born prematurely with blindness and
Immunosuppressive drugs in pregnancy iii29
cerebral palsy [21]. An ongoing study of the Organization of
Teratology Information Specialists (OTIS) prospectively collects
data on intrauterine exposures to LEF. The preliminary results
(Congress abstracts) of 63 RA pregnancies exposed to LEF during
the first trimester have not shown an increase in miscarriage or
congenital malformations compared with 108 RA pregnancies not
exposed to LEF. A slight increase in prematurity was noted in the
infants exposed to LEF. The available experience limited to a total
of 74 pregnancies leaves the question open whether LEF is a
human teratogen. The case report cited above does not prove
a causal relationship between LEF and the observed anomalies.
Because of the small number of pregnancies studied, LEF should
be stopped before a planned pregnancy and conception attempted
only after a washout with cholestyramine or active charcoal.
Long-term effects of intrauterine exposure to fluorinated
corticosteroids
Several animal studies and a few human studies have raised
concern about possible negative long-term effects of betametha-
sone and dexamethasone given to accelerate fetal lung maturation.
It was suspected that antenatal exposure to betamethasone might
result in insulin resistance in adult offspring, but a 30-yr follow-up
of a randomized controlled trial found no clinical effect on
cardiovascular risk factors such as body size, blood lipids, blood
pressure, prevalence of diabetes or history of cardiovascular
disease [22].
No negative effects on the neuropsychological development of
a small cohort of 16 anti-Ro/SSA-positive children exposed in
utero to very high dosages of dexamethasone (mean total dose
186.6mg) were found [23]. This dose is much higher than those
used to enhance fetal lung maturity, and these findings seem
reassuring in view of the large number of infants exposed in the
past to repeated antenatal courses of therapy with fluorinated
corticosteroids.
Own cases
The authors reported 49 pregnancies that had occurred during
therapy with biological agents and immunosuppressive drugs
during 2006–07 (Table 1). These cases add to our knowledge,
particularly for CsA and AZA where most pregnancy experience
stems from transplant recipients. Not unexpectedly, most cases
of prematurity occurred in patients with SLE independent of
therapy. Except for one prematurely born child that died with
multiple cardiac malformations, the other pregnancies with
known outcome ended with the delivery of healthy children.
Conclusion
Experience with pregnancy exposure to biological agents and new
immunosuppressive drugs is slowly accumulating. In regard to
TNF- inhibitors, safety issues are still under debate. LEF may
turn out not to be a human teratogen; however, larger patient
cohorts are needed. The safety of tacrolimus during pregnancy is
suggested by new data whereas MMF appears to carry a
significant teratogenic risk. There remains a substantial lack on
studies investigating the transfer of biological agents and
immunosuppressive drugs to breast milk and their effect on the
nursing child. Likewise, more investigations in regard to
immunosuppressive drugs and gonadal function in men are
needed. Overall, the new data from the years 2006–07 have not
changed the recommendations given in the consensus paper
of 2006 [1].
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